Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics
Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics PASADENA, Calif. — November 2, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that a paper further validating the drug development
View HTML
Toggle Summary Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer
Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer PASADENA, Calif. — October 27, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has appointed Bruce Given, M.D. to the position of Chief Operating Officer of the Company effective October 26, 2011.
View HTML
Toggle Summary Arrowhead Research Corporation Acquires Roche RNA Assets and Site
Three New Delivery Technologies, Broad RNAi IP, and Advanced Operations to Drive Clinical Development, Partnerships, and Revenue Roche Takes Equity Stake in Arrowhead and Rights to Negotiate Future RNAi Candidates Conference Call Scheduled for Today at 4:30 PM ET
View HTML
Toggle Summary Arrowhead Research Corporation Completes $5.5 Million Private Placement
At Market Offering Led by Noted Investor, Jim Mellon; Proceeds to Fund Nanomedicine Programs
View HTML
Toggle Summary Arrowhead Reports Fiscal 2011 Third Quarter Financial Results
Calando Completes Phase 1 Trial; Initiates Phase 1b
View HTML
Toggle Summary Arrowhead Research to Report Fiscal 2011 Third Quarter Financial Results and Host Conference Call on Monday, August 8, 2011
Arrowhead Research to Report Fiscal 2011 Third Quarter Financial Results and Host Conference Call on Monday, August 8, 2011 PASADENA, Calif. — August 1, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2011 third quarter
View HTML
Toggle Summary Arrowhead Research Announces Oncology Expert Timothy J. Triche to Join Calando Scientific Advisory Board
Arrowhead Research Announces Oncology Expert Timothy J. Triche to Join Calando Scientific Advisory Board PASADENA, Calif. — July 26, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced
View HTML
Toggle Summary Arrowhead Research to Present at Two Nanomedicine-Focused Events in London
Arrowhead Research to Present at Two Nanomedicine-Focused Events in London PASADENA, Calif. – June 21, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief
View HTML
Toggle Summary Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview
Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview PASADENA, Calif. – June 16, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today
View HTML
Toggle Summary Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement
Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement PASADENA, Calif. – June 9, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on June 7, 2011, it received a notification from the NASDAQ Stock Market indicating that
View HTML